+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Disease Diagnostics Market by Offering, Disease Type, End-User - Global Forecast 2026-2032- Product Image
Liver Disease Diagnostics Market by Offering, Disease Type, End-User - Global Forecast 2026-2032- Product Image
Sale

Liver Disease Diagnostics Market by Offering, Disease Type, End-User - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5533043
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Liver Disease Diagnostics Market is projected to reach USD 15.89 Billion in 2026. It is expected to continue growing at a CAGR of 9.51%, reaching USD 27.57 Billion by 2032.

Liver disease diagnostics are moving from reactive confirmation of advanced disease toward earlier, risk-based detection across primary care, hepatology, infectious disease, oncology, and transplant pathways.

The clinical need is substantial. The World Health Organization reported that viral hepatitis caused about 1.3 million deaths in 2022, while hepatitis B and C affected an estimated 304 million people worldwide. In parallel, metabolic dysfunction-associated steatotic liver disease, formerly NAFLD, is estimated in peer-reviewed global analyses to affect roughly one in three adults. These trends are increasing demand for liver function tests, hepatitis serology, molecular diagnostics, fibrosis biomarker panels, elastography, ultrasound, CT, MRI, and point-of-care testing.

For market participants, the opportunity is strongest where diagnostics improve early case finding, stratify fibrosis risk, guide antiviral or metabolic therapy, and support surveillance for cirrhosis and hepatocellular carcinoma.

Transformative Shifts in Liver Disease Diagnostics

The liver disease diagnostics landscape is being reshaped by three structural shifts: the rising burden of metabolic liver disease, renewed public health focus on viral hepatitis elimination, and the need to reduce avoidable late-stage cirrhosis detection.

Clinical pathways are shifting from single-test evaluation to integrated diagnostic algorithms. Routine liver enzyme testing is increasingly paired with platelet count-based scores such as FIB-4, enhanced liver fibrosis panels, transient elastography, magnetic resonance elastography, and targeted molecular assays. This combination supports non-invasive fibrosis staging and reduces dependence on liver biopsy, which remains valuable but is limited by sampling error, cost, and procedural risk.

Healthcare systems are also prioritizing decentralization. Community-based hepatitis testing, reflex laboratory workflows, home specimen collection, and digital referral pathways are improving access while shortening the time between abnormal screening results and specialist management.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding value across liver disease diagnostics by improving image interpretation, risk prediction, workflow triage, and longitudinal monitoring. AI-enabled tools are being evaluated for ultrasound quality enhancement, liver lesion characterization, CT and MRI segmentation, steatosis quantification, and fibrosis estimation.

The cumulative impact is operational as well as clinical. Algorithms can help prioritize patients with abnormal liver function tests, combine laboratory and electronic health record data to flag elevated fibrosis risk, and reduce reporting variability in imaging-heavy pathways. In hepatocellular carcinoma surveillance, AI has potential to support earlier detection when curative options are more feasible.

Adoption must remain evidence-led. Industry leaders should validate AI across diverse populations, document performance by disease etiology and ethnicity, monitor bias, and align with medical device software regulations, data privacy rules, and clinician-in-the-loop governance.

Key Regional Insights

Asia-Pacific is a high-priority region because it combines large populations, persistent hepatitis B burden, rapidly rising metabolic liver disease, and expanding diagnostic infrastructure in China, India, Japan, South Korea, and Australia. The WHO has identified the Western Pacific and South-East Asia as major contributors to the global viral hepatitis burden, reinforcing the need for scalable hepatitis B and C testing, liver function assessment, fibrosis stratification, and hepatocellular carcinoma surveillance. North America benefits from advanced reimbursement frameworks, strong imaging capacity, and growing adoption of non-invasive fibrosis testing, especially as obesity, diabetes, alcohol-related liver disease, and MASLD increase clinical demand.

Latin America shows increasing need for affordable hepatitis testing, liver enzyme screening, and fibrosis risk stratification, with Brazil and Mexico serving as key access hubs as health systems expand prevention and chronic disease management. Europe is shaped by structured public health programs, EU regulatory oversight, and strong uptake of elastography, biomarker-led pathways, and guideline-based hepatitis elimination initiatives.

The Middle East faces rising metabolic risk linked to diabetes and obesity, supporting demand for early liver disease diagnostics, non-invasive fibrosis assessment, and surveillance pathways for high-risk patients. Africa remains underserved despite meaningful viral hepatitis burden, making scalable serology, point-of-care testing, confirmatory molecular diagnostics, laboratory quality systems, and referral infrastructure essential to improve detection and continuity of care.

Key Group Insights

ASEAN demand is supported by large screening-eligible populations, hepatitis B prevalence in several member states, and expanding private hospital networks that are increasing access to liver enzyme testing, hepatitis serology, ultrasound, and fibrosis assessment. The GCC is investing in digital health, specialty care, and preventive screening, while high diabetes and obesity prevalence increase demand for MASLD diagnostics, non-invasive fibrosis assessment, and integrated referral pathways.

The European Union is a leader in standardized regulatory pathways, in vitro diagnostic oversight, and public health-led hepatitis elimination strategies, supporting adoption of validated laboratory assays, elastography, and evidence-based clinical algorithms. BRICS countries represent volume-driven opportunity due to large patient pools, domestic diagnostic manufacturing, and expanding insurance coverage, though access levels vary widely across urban and rural settings.

G7 markets lead in advanced imaging, molecular diagnostics, AI validation, laboratory automation, and clinical guideline adoption, strengthening uptake of integrated diagnostic pathways for hepatitis, MASLD, cirrhosis, and liver cancer surveillance. NATO countries overlap with many high-income health systems where resilient supply chains, data security, interoperable diagnostic networks, and continuity of essential testing are strategic priorities for liver disease diagnostics.

Key Country Insights

The United States leads in advanced liver disease diagnostics through broad availability of molecular testing, elastography, MRI, and specialty hepatology networks, while Canada emphasizes guideline-based hepatitis and fibrosis assessment through public healthcare systems. Mexico and Brazil show strong need for scalable hepatitis testing, liver enzyme screening, and non-invasive fibrosis tools as metabolic disease increases and access initiatives expand across primary care and reference laboratories.

In Europe, the United Kingdom, Germany, France, Italy, and Spain support adoption through structured care pathways, public health screening programs, advanced imaging capacity, and growing use of non-invasive fibrosis assessment, while Russia presents demand linked to viral hepatitis, alcohol-related liver disease, and uneven regional access to specialist diagnostics. China and India represent major volume opportunities due to large populations and combined viral and metabolic liver disease burden, with expanding diagnostic infrastructure supporting hepatitis testing, liver function panels, ultrasound, molecular assays, and fibrosis risk stratification.

Japan, Australia, and South Korea offer sophisticated diagnostic ecosystems with strong imaging capacity, aging populations, robust laboratory networks, and high readiness for AI-assisted workflows, laboratory automation, and hepatocellular carcinoma surveillance. These countries also benefit from guideline-oriented clinical practice and established specialty care systems that support early identification of fibrosis, cirrhosis, and liver cancer risk.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated, non-invasive diagnostic pathways that connect liver function tests, hepatitis assays, fibrosis scores, elastography, and imaging into actionable care decisions. The strongest solutions will shorten time to diagnosis, identify advanced fibrosis earlier, and integrate seamlessly into primary care and specialist workflows.

Organizations should build evidence packages that demonstrate sensitivity, specificity, cost-effectiveness, workflow impact, and improved referral quality. Partnerships with laboratories, radiology networks, digital health vendors, payers, and public health agencies can expand access and improve test adherence.

Strategic investment should focus on affordable point-of-care testing, multiplex molecular platforms, AI-enabled imaging, companion diagnostics for emerging liver therapies, and interoperable data systems that support longitudinal monitoring and population health management.

Research Methodology

This executive summary is based on a structured secondary research approach aligned with established market intelligence practices. Sources considered include public health datasets, peer-reviewed hepatology literature, clinical guideline publications, regulatory frameworks, technology adoption evidence, and documented trends across laboratory diagnostics, imaging, molecular testing, and digital health.

The analysis emphasizes verified, data-backed indicators such as disease burden, diagnostic pathway evolution, technology readiness, regional healthcare infrastructure, and public health priorities. Qualitative synthesis was used to connect epidemiology, clinical practice, reimbursement dynamics, regulatory requirements, and innovation trends.

Insights were reviewed for relevance to liver disease diagnostics, including hepatitis testing, liver function testing, fibrosis assessment, MASLD evaluation, elastography, imaging, AI-enabled diagnostics, and hepatocellular carcinoma surveillance. No market sizing, market share, or forecasting assumptions were applied.

Conclusion

The liver disease diagnostics market is entering a high-impact phase as healthcare systems confront the combined burden of viral hepatitis, MASLD, alcohol-related liver disease, cirrhosis, and liver cancer. Early detection, integrated testing algorithms, and non-invasive fibrosis assessment are now central to improving outcomes and reducing downstream treatment costs.

Future market leadership will depend on diagnostic accuracy, affordability, evidence generation, digital integration, regulatory readiness, and equitable access. Organizations that connect laboratory, imaging, molecular, and AI-enabled insights into practical clinical pathways will be best positioned to support earlier intervention and measurable improvements in liver health.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Liver Disease Diagnostics Market, by Offering
7.1. Biopsy Techniques
7.1.1. Laparoscopic Liver Biopsy
7.1.2. Percutaneous Liver Biopsy
7.1.3. Transvenous Liver Biopsy
7.2. Blood-Based Tests
7.2.1. Alanine Transaminase Test
7.2.2. Aspartate Transaminase Test
7.2.3. Gamma-Glutamyl Transpeptidase Test
7.3. Endoscopy
7.4. Imaging Diagnostics
7.4.1. CT Scan
7.4.2. MRI
7.4.3. Ultrasound
8. Liver Disease Diagnostics Market, by Disease Type
8.1. Acute Hepatitis
8.2. Alcoholic Liver Disease
8.3. Chronic Hepatitis
8.4. Cirrhosis
8.5. Hepatocellular Carcinoma
8.6. Non-Alcoholic Fatty Liver Disease
9. Liver Disease Diagnostics Market, by End-User
9.1. Diagnostic Laboratories
9.2. Hospitals
9.3. Research Institutes
10. Asia-Pacific Liver Disease Diagnostics Market
11. North America Liver Disease Diagnostics Market
12. Latin America Liver Disease Diagnostics Market
13. Europe Liver Disease Diagnostics Market
14. Middle East Liver Disease Diagnostics Market
15. Africa Liver Disease Diagnostics Market
16. ASEAN Liver Disease Diagnostics Market
17. GCC Liver Disease Diagnostics Market
18. European Union Liver Disease Diagnostics Market
19. BRICS Liver Disease Diagnostics Market
20. G7 Liver Disease Diagnostics Market
21. NATO Liver Disease Diagnostics Market
22. United States Liver Disease Diagnostics Market
23. Canada Liver Disease Diagnostics Market
24. Mexico Liver Disease Diagnostics Market
25. Brazil Liver Disease Diagnostics Market
26. United Kingdom Liver Disease Diagnostics Market
27. Germany Liver Disease Diagnostics Market
28. France Liver Disease Diagnostics Market
29. Russia Liver Disease Diagnostics Market
30. Italy Liver Disease Diagnostics Market
31. Spain Liver Disease Diagnostics Market
32. China Liver Disease Diagnostics Market
33. India Liver Disease Diagnostics Market
34. Japan Liver Disease Diagnostics Market
35. Australia Liver Disease Diagnostics Market
36. South Korea Liver Disease Diagnostics Market
37. Competitive Landscape
37.1. Market Concentration Analysis, 2025
37.1.1. Concentration Ratio (CR)
37.1.2. Herfindahl Hirschman Index (HHI)
37.2. Recent Developments & Impact Analysis, 2025
37.3. Product Portfolio Analysis, 2025
37.4. Benchmarking Analysis, 2025
38. Company Profiles
38.1. Abbott Laboratories
38.2. Amgen Inc.
38.3. Argon Medical Devices, Inc.
38.4. Bayer AG
38.5. Becton, Dickinson and Company
38.6. Bio-Rad Laboratories, Inc.
38.7. BioMérieux SA
38.8. Boston Scientific Corporation
38.9. Cook Medical Incorporated
38.10. Echosens by Astor Partners S.r.l.
38.11. Epigenomics AG
38.12. F. Hoffmann-La Roche Ltd.
38.13. Fujifilm Holdings Corporation
38.14. Hepatiq, Inc.
38.15. Hologic, Inc.
38.16. Horiba, Ltd.
38.17. Koninklijke Philips N.V.
38.18. Laboratory Corporation of America Holdings
38.19. Medtronic PLC
38.20. Merck & Co., Inc.
38.21. Perspectum Ltd.
38.22. Qiagen N.V.
38.23. Quest Diagnostics Incorporated
38.24. Randox Laboratories Ltd.
38.25. Ri.Mos. Srl
38.26. Siemens Healthineers AG
38.27. Thermo Fisher Scientific, Inc.
List of Figures
FIGURE 1. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
FIGURE 15. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 33. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 35. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 45. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 46. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 47. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 48. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BIOPSY TECHNIQUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL BIOPSY TECHNIQUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL BIOPSY TECHNIQUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL LAPAROSCOPIC LIVER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LAPAROSCOPIC LIVER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LAPAROSCOPIC LIVER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PERCUTANEOUS LIVER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PERCUTANEOUS LIVER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PERCUTANEOUS LIVER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL TRANSVENOUS LIVER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL TRANSVENOUS LIVER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL TRANSVENOUS LIVER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BLOOD-BASED TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL BLOOD-BASED TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL BLOOD-BASED TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ALANINE TRANSAMINASE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ALANINE TRANSAMINASE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ALANINE TRANSAMINASE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ASPARTATE TRANSAMINASE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ASPARTATE TRANSAMINASE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ASPARTATE TRANSAMINASE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GAMMA-GLUTAMYL TRANSPEPTIDASE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GAMMA-GLUTAMYL TRANSPEPTIDASE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GAMMA-GLUTAMYL TRANSPEPTIDASE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ENDOSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ENDOSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ENDOSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL IMAGING DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL IMAGING DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL IMAGING DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CT SCAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CT SCAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CT SCAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MRI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MRI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MRI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ACUTE HEPATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ACUTE HEPATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ACUTE HEPATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ALCOHOLIC LIVER DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ALCOHOLIC LIVER DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ALCOHOLIC LIVER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CHRONIC HEPATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CHRONIC HEPATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CHRONIC HEPATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CIRRHOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CIRRHOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CIRRHOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 98. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 100. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 101. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 102. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 103. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 104. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 112. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 114. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 115. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 116. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 117. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 118. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 119. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 121. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 122. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 123. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 124. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 125. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 126. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 128. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 129. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 130. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 131. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 132. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 140. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 142. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 143. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 144. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 145. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 146. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 147. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 148. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 149. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 150. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 151. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 152. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 153. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 154. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 155. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 156. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 157. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 158. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 159. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 160. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 161. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 162. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 163. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 164. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 165. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 166. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 167. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 168. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 169. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 170. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 171. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 172. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 173. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 174. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 175. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 176. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 177. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 178. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 179. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 180. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 181. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 182. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 183. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 184. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 185. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 186. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 187. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 188. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 189. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 190. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 191. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 192. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 193. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 194. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 195. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 196. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 197. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 198. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 199. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 200. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 201. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 202. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 203. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 204. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 205. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 206. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 207. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 208. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 209. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 210. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 211. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 212. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 213. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 214. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 215. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 216. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 217. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 218. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 219. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 220. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 221. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 222. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 223. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 224. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 225. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 226. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 227. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 228. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 229. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 230. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 231. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 232. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 233. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 234. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 235. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 236. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 237. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 238. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 239. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 240. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 241. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 242. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 243. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 244. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 245. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 246. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 247. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 248. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 249. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 250. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 251. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 252. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 253. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 254. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 255. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 256. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 257. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 258. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 259. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 260. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
TABLE 261. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
TABLE 262. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
TABLE 263. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 264. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 265. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Liver Disease Diagnostics market report include:
  • Abbott Laboratories
  • Amgen Inc.
  • Argon Medical Devices, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMérieux SA
  • Boston Scientific Corporation
  • Cook Medical Incorporated
  • Echosens by Astor Partners S.r.l.
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • Hepatiq, Inc.
  • Hologic, Inc.
  • Horiba, Ltd.
  • Koninklijke Philips N.V.
  • Laboratory Corporation of America Holdings
  • Medtronic PLC
  • Merck & Co., Inc.
  • Perspectum Ltd.
  • Qiagen N.V.
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd.
  • Ri.Mos. Srl
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.

Table Information

Report AttributeDetails
No. of Pages181
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 15.89 Billion
Forecasted Market Value ( USD ) by 2032 $ 27.57 Billion
Compound Annual Growth Rate9.5%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Liver Disease Diagnostics - Global Strategic Business Report - Product Image

Liver Disease Diagnostics - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Liver Disease Diagnostics Market Size, Share & Trends Analysis Report by Diagnosis Technique (Imaging, Laboratory Tests, Endoscopy, Biopsy), by Disease (NAFLD, NASH, Fibrosis, Cirrhosis), by End Use (Hospitals, Laboratories), by Region, and Segment Forecasts, 2025-2033 - Product Image

Liver Disease Diagnostics Market Size, Share & Trends Analysis Report by Diagnosis Technique (Imaging, Laboratory Tests, Endoscopy, Biopsy), by Disease (NAFLD, NASH, Fibrosis, Cirrhosis), by End Use (Hospitals, Laboratories), by Region, and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From
Liver Disease Diagnostics Market Report 2026 - Product Image

Liver Disease Diagnostics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Liver Cancer Diagnostics Market - Global Forecast 2026-2032 - Product Image

Liver Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Liver Fibrosis Drugs Market by Drug Class, Mechanism of Action, Route of Administration, Distribution Channel - Global Forecast 2026-2032 - Product Image

Liver Fibrosis Drugs Market by Drug Class, Mechanism of Action, Route of Administration, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From

About the Liver Disease Diagnostics Market

The Liver Disease Diagnostics market comprises various tests and procedures used for the detection and monitoring of hepatic conditions. These diagnostics are essential in the healthcare landscape as the liver is a critical organ involved in numerous metabolic processes, and its diseases can have widespread health implications. Liver function tests (LFTs), imaging tests such as ultrasound, CT scans, and MRIs, biopsy procedures, and genetic testing form the core of liver diagnostics. The advancement of non-invasive imaging and biomarker identification has enhanced the ability to diagnose liver conditions accurately at an early stage. In addition to traditional diagnostics, this market is also seeing innovation through the development of point-of-care testing kits, improved serological assays, and the integration of artificial intelligence for better image interpretation. The demand for liver disease diagnostics is spurred by increasing prevalence of liver disease, a growing focus on preventive healthcare, and the adoption of lifestyle changes that may affect liver health. Notable companies in the Liver Disease Diagnostics market include Siemens Healthineers, Abbott Laboratories, Roche Diagnostics, Bio-Rad Laboratories, and Quest Diagnostics. These companies provide a range of diagnostic products and services that cater to the varied needs of detecting and managing liver-related medical conditions. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.